Private label ranitidine
This article was originally published in The Tan Sheet
Executive Summary
Abbreviated NDAs for 75 mg ranitidine tablets (Warner-Lambert's Zantac 75) submitted by Ranbaxy Pharmaceuticals (ANDAs 75-254, 75-132), Genpharm (75-497), Zenith Goldline Pharmaceuticals (75-296) and Chelsea Laboratories (75-212) were approved by FDA Jan. 14. The companies may begin shipping the product now. Granutec launched its generic ranitidine July 19 with six months of private label marketing exclusivity. Watson Pharmaceuticals, which plans to launch a private label nicotine polacrilex gum soon, also has plans to launch private label ranitidine. The product will be manufactured by Aventis. Watson said final ANDA approval is pending
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning